JesÃºs Duque-Afonso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6361336/publications.pdf

Version: 2024-02-01

31	383	759055 12	839398 18
papers	citations	h-index	g-index

33	33	33	703
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The epigenetics of breast cancer â€“ Opportunities for diagnostics, risk stratification and therapy. Epigenetics, 2022, 17, 612-624.	1.3	13
2	Comparison of fludarabineâ€“melphalan and fludarabineâ€“treosulfan as conditioning prior to allogeneic hematopoietic cell transplantationâ€”a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2022, 57, 1269-1276.	1.3	6
3	Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. Cancer Gene Therapy, 2022, 29, 1751-1760.	2.2	7
4	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. Cancers, 2022, 14, 3307.	1.7	1
5	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 110-120.	1.3	8
6	Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 327-333.	1.3	5
7	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. Bone Marrow Transplantation, 2021, 56, 841-852.	1.3	12
8	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	1.7	27
9	AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms. Oncogene, 2021, 40, 5665-5676.	2.6	18
10	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Advances, 2021, 5, 4327-4337.	2.5	9
11	Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation. Transfusion and Apheresis Science, 2020, 59, 102594.	0.5	14
12	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. Diagnostics, 2020, 10, 550.	1.3	8
13	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective singleâ€centre analysis. British Journal of Haematology, 2020, 190, e110-e114.	1.2	10
14	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. Cancers, 2020, 12, 169.	1.7	5
15	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica, 2020, 105, 1183-1188.	1.7	46
16	Loss of the Fanconi anemiaâ€“associated protein NIPA causes bone marrow failure. Journal of Clinical Investigation, 2020, 130, 2827-2844.	3.9	8
17	Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. Clinical Chemistry and Laboratory Medicine, 2019, 57, 641-647.	1.4	25
18	The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2. Blood, 2019, 134, 3741-3741.	0.6	0

#	Article	IF	Citations
19	Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. Clinical Biochemistry, 2018, 52, 137-141.	0.8	19
20	SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. Cell Reports, 2018, 23, 1166-1177.	2.9	20
21	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2018, 24, 2277-2284.	2.0	19
22	Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses. Leukemia, 2016, 30, 2116-2119.	3.3	15
23	The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leukemia Research, 2014, 38, 340-345.	0.4	10
24	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transplantation, 2013, 48, 1098-1103.	1.3	20
25	Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. British Journal of Haematology, 2011, 153, 612-622.	1.2	13
26	The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene, 2011, 30, 3062-3072.	2.6	45
27	Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells. Blood, 2010, 116, 2474-2474.	0.6	0
28	Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 1266-1266.	0.6	0
29	Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4660-4660.	0.6	0
30	Epigenetic Repression of the Adaptor Molecule LAT2 by the Leukemic Fusion Protein AML1/ETO.. Blood, 2007, 110, 987-987.	0.6	0
31	The AML1/ETO Target LAT2 Membrane Adaptor Molecule Is Regulated during Normal Monocytic Differentiation.. Blood, 2007, 110, 2401-2401.	0.6	0